MetaCap

Actinium Pharmaceuticals (Delaware) Insider Trades

NYSE: ATNMHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.05-0.02 (-1.87%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Last 12 months

Purchases
0 · $0
Sales
0 · $0
Shares bought / sold
0 / 0
Net activity
Net buying $0

Actinium Pharmaceuticals (Delaware) insider activity

Over the last 12 months, Actinium Pharmaceuticals (Delaware) insiders reported 8 transactions on SEC Form 4: 0 open-market purchases and 0 sales. The most recent filing shows David Matthew T (Chief Financial Officer) reporting a transaction in 250,000 shares on Oct 14, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put ATNM's ownership changes in context.

Summary generated from market data by MetaCap's automated system. Methodology

ATNM insider transactions

Actinium Pharmaceuticals (Delaware) insider transactions
DateInsiderTypeSharesValueFiling
Oct 14, 2026David Matthew TChief Financial OfficerAward250,000—Form 4
Sep 2, 2026Steinhart Richard IDirectorAward62,800—Form 4
Sep 2, 2026SETH SANDESHChief Executive OfficerAward1,027,274—Form 4
Sep 2, 2026SETH SANDESHChief Executive OfficerAward753,600—Form 4
Sep 2, 2026Almenoff June SherieDirectorAward18,000—Form 4
Sep 2, 2026Chell Jeffrey W.DirectorAward61,600—Form 4
Sep 2, 2026Nicholson, C. DavidDirectorAward62,800—Form 4
Sep 2, 2026Shetty AjitDirectorAward61,600—Form 4
Aug 18, 2025SETH SANDESHChief Executive OfficerTax withholding120,900$206.74KForm 4
Aug 17, 2022SETH SANDESHChief Executive OfficerAward300,000—Form 4

Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4

Related